Servier's New and Updated Data at 2025 ASH Annual Meeting Highlight Commitment to Hematology Research

Presentations include seven company-sponsored abstracts and 11 investigator-initiated studies. Results from a Phase 1 analysis of TIBSOVO® (ivosidenib) in patients with newly diagnosed IDH1-mutated AML who are eligible for chemotherapy will be featured in an oral presentation. BOSTON, Nov....